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Stlmma.ry 
A major obstacle to the development of T cell therapy for the treatment of human tumors has 
been the difficulty generating T cells specifically  reactive with the tumor. Most of the characterized 
human tumor antigens have been dassified as tumor associated, because of demonstrable expression 
at low levels in some normal cells, and thus have not been extensively studied as potential targets 
of a therapeutic immune response.  However, the quantitative difference in expression  of such 
antigens between the tumor and normal cells might permit the generation of antigen-specific 
T cells capable of selective antitfimor and not autoimmune activity. To address this issue, transgenic 
(TG) mice were generated that expressed low levels of Friend murine leukemia virus (FMuLV) 
envelope protein in lymphoid cells under the control of an immunoglobulin  promoter. This protein 
is expressed at high levels by a Friend virus-induced erythroleukemia of C57BL/6 (B6) origin, 
FBL, and has been shown to serve as an efficient tumor-specific rejection antigen in B6 mice. 
The env-TG mice were tolerant to envelope,  as reflected by the failure to detect an envelope- 
specific response after in vivo priming and in vitro stimulation with preparations of FMuLV 
envelope. However, adoptively transferred envelope-specific T cells from immunized non-TG B6 
mice mediated complete eradication of FBL tumor cells in TG mice, and did not induce detectable 
autoimmune damage to TG lymphoid tissues. The transferred immune cells were not permanently 
inactivated in the TG mice, since donor T  cells responded to envelope after removal from the 
TG mice. The lack of autoimmune injury did not reflect inadequate expression of envelope by 
TG lymphocytes for recognition by T cells, since TG lymphocytes functioned effectively in vitro 
as stimulators for envelope-specific T cells. The results suggest that this and analogous strains 
of TG mice may prove useful for elucidating principles for the generation and therapeutic use 
of tumor-reactive T  cells specific for tumor-associated antigens. 
E 
ffector T cells have been demonstrated to mediate pro- 
tective and therapeutic immune responses against tumors 
in both animals and humans. The generation of such responses 
requires that the tumor cells express an antigen recognizable 
by host peripheral T cells. The ideal tumor antigens are im- 
munogenic proteins uniquely expressed on neoplastic cells. 
Although there are many examples of such antigens in ex- 
perimental animal tumors as well as more limited examples 
in human tumors, most of the human tumor antigens that 
have been characterized are also detected at low levels in some 
normal cells (1, 2). Efforts to evaluate such antigens as targets 
for the generation of therapeutic antitumor T cell responses 
have been limited largely due to two issues: (a) the host is 
likely  to  be  tolerant  to  these  tumor-associated  antigens 
(TAA) l since they are normal self-proteins  such as differen- 
tiation antigens; and (b) even if methods to break tolerance 
and  elicit  host  T  cell responses  to  the antigen could be 
i Abbreviations used in thispaper: CY, cyclophosphamide;  E/z, heavy chain 
/~ enhancer; FBL, Friend virus-induced leukemia of B6 origin; FMuLV, 
Friend murine leukemia virus; hGH, human growth hormone; Pg, heavy 
chain # Vh promoter; SA, splice acceptor  site; SD, splice donor site; TAA, 
tumor-associated antigen; TG, transgenic. 
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titumor activity but also the capability of mediating autoim- 
mune damage to the normal tissues expressing the antigen. 
Advances in our understanding of the basis and maintenance 
of tolerance to self-antigens have made it possible to reex- 
amine such possible target antigens.  Studies in transgenic (TG) 
mice, in which genes have been introduced into the germline 
and consequently encode new "self-proteins;' have revealed 
that  the interaction between host T  cells  and self-antigens 
can result in several distinct outcomes. Intrathymic expres- 
sion or presentation of self-antigens usually leads to deletion 
of self-reactive  T  cells  (3-5).  By contrast,  self-antigens ex- 
pressed only in peripheral (extrathymic) tissues often induce 
tolerance by nondeletional mechanisms, such as donal anergy 
(6, 7), and/or downregulation of the TCR (8). Despite ap- 
parent tolerance in vivo, T cells specific for some extrathymic 
self-antigens can be activated under appropriate conditions 
in  vitro  (9-11)  and  in  vivo (12,  13).  Moreover,  some ex- 
trathymic  self-antigens  may be  expressed  in  such  limited 
amounts or found in normal tissues expressing a sufficiently 
low density of MHC molecules that the antigens fail to in- 
duce tolerance or serve as targets for autoimmune reactivity 
(14, 15). These findings suggest that some TAA may be capable 
of serving as targets for antitumor T  cell therapy, a percep- 
tion further supported by the recent demonstration that tumor- 
specific  T  cells isolated from a patient  with melanoma are 
specific  for a protein encoded by a nonmutated  gene (16). 
Our laboratory has previously described and extensively 
characterized an adoptive T cell therapy model for the treat- 
ment of a disseminated Friend virus-induced leukemia of B6 
origin, FBL (17). FBL expresses Friend murine leukemia virus 
(FMuLV) env- and gag-encoded tumors antigens (18, 19), and 
FBL-reactive  CD8 +  CTL  have  been  shown  to  predomi- 
nantly recognize FMuLV gag-encoded  proteins while FBL- 
reactive CD4 + Th cells recognize FMuLV env-encoded  an- 
tigens (19). Each T cell subset, independent of the other, can 
mediate complete eradication  of disseminated FBL tumor cells 
in adoptive T  cell therapy of B6 mice (18,  20,  21). 
To investigate the potential for using TAA as targets for 
adoptive T cell therapy of tumors, lines of B6 transgenic mice 
expressing FMuLV genes under the control of various tissue- 
specific promoters have been generated.  These TG animals 
provide a model, with the FBL tumor,  to evaluate:  (a) the 
basis of host T  cell tolerance to TAA; (b) the requirements 
for breaking such tolerance to induce a host T  cell response 
to TAA; and (c) the consequences of inducing such a T cell 
response with regard to both tumor eradication and autoim- 
mune injury. This paper is the initial description and charac- 
terization of a TG mouse line expressing low levels of FMuLV 
envelope in the lymphoid tissues, under the control of the 
mouse Ig heavy chain/~ enhancer (E/x) and Vh promoter (P/~) 
element. Our results show that FMuLV envelope antigen ex- 
pression in TG lymphoid tissues induces T cell tolerance, in 
that host T cells cannot be readily primed to FMuLV enve- 
lopes in vivo. In contrast, FMuLV envelope-specific primed 
T  cells derived from non-TG mice are not inactivated after 
transfer into env-TG mice, and mediate eradication of envelope- 
expressing FBL tumor calls without causing detectable au- 
toimmune destruction of the lymphoid tissue expressing low 
levels of FMuLV envelope. The possible mechanisms are dis- 
cussed. 
Materials  and Methods 
Mice.  C57BL/6  (H-2  ~,  Thy-1.2,  denoted  B6)  mice  and 
breeding pairs of congenic B6.PL (74NS) (H-2  b, Thy-l.1, denoted 
B6/Thy-l.1) mice were obtained from The Jackson Laboratory (Bar 
Harbor,  ME). 
Cell Lines and  Viruses.  FBL expresses FMuLV env-  and gag- 
encoded products  and dass I but not class II H-2  b MHC mole- 
cules (18, 19). FMuLV virions, live recombinant vaccinia virus ex- 
pressing the FMuLV env gene (22), and vaccinia virus were kindly 
provided by Dr. Bruce Chesebro (Rocky Mountain Laboratories, 
Hamilton,  MT). 
Gene  Construction.  The  pIg-ENV-human  growth  hormone 
(hGH) fusion gene (Fig. 1) was constructed using a multi-step pro- 
cedure. A 2.2-kb EcoRI-SstI fragment of plasmid PIC/~PRE8 (W. 
Kindsvogel, ZymoGenetics, Seattle, WA), containing the combined 
E/z and P/z sequences derived from the mouse Ig heavy chain gene 
(23, 24), was cloned into PUC19 to generate plasmid PJH1. A 2.2- 
kb XbaI-PstI fragment of FMuLV clone 57, containing the entire 
FMuLV env  gene (25), was subdoned into PUC18 to generate 
plasmid PWK4. A 2.2-kb XbaI-HindlII fragment, containing the 
FMuLV env gene, was then isolated from FWK4 and inserted into 
the XbaI and HindIII sites of PJH1, immediately downstream  of 
the E/~/P/z segment, to generate plasmid PJH2. Finally, a 2.1-kb 
BamHI-HindIII fragment containing the hGH gene sequence ex- 
tending  from the BamHI site in the first exon to the EcoRI site 
after the poly(A) addition  signal (26) was isolated from plasmid 
P107 (27) and inserted with a synthetic  linker into the HindIII 
site of PJH2. The final plasmid (pIg-ENV-hGH) contains the E/z/P~ 
regulatory elements, the FMuLV env gene and hGH gene oriented 
5' to 3' (Fig. 1). A 6.5-kb EcoRI fragment of pIg-ENV-hGH  was 
isolated for microinjection. 
The pIg-ENV-3'LTR fusion gene was constructed in multiple 
steps. Complimentary  oligonudeotides  were synthesized to con- 
tain bases 170-215 of FMuLV clone 57, which includes the splice 
donor  site (SD) for FMuLV at position  206 (EMBL/GenBank 
Nucleotide  Sequence Databases), and new SalI and SphI sites at 
the 5' and 3' ends, respectively. This synthetic oligonucleotide was 
joined at the 5' SphI site of a 4.1-kb SphI-HindIII  fragment  of 
FMuLV clone 57, which includes the splice acceptor site (SA), en- 
tire env coding region,  and 3' LTR sequence of FMuLV clone 57 
(25, 28), and then cloned into PUC 18 at SalI-HindIII  sites to 
generate plasmid PJHll. Finally, a 2.2-kb EcoRI-SalI fragment of 
PJH1, which contains the combined E#/P/~ regulatory sequence, 
was inserted between the EcoRI and SphI sites ofpJHll, immedi- 
ately upstream of the FMuLV env  gene. The final plasmid (pIg- 
ENV-YLTR) contains the E/z/P/z control elements and the FMuLV 
env-YLTR gene (Fig. 1). A 6.3-kb EcoRI-HindlII fragment ofpIg- 
ENV-3'LTR  was used for microinjection. 
Generation of 7G Mice,  Transgenic mice were generated using 
standard methods (29). Briefly, purified linear DNA (2 ng//zl) was 
injected into pronudei of B6 zygotes, and viable zygotes were im- 
planted into the oviducts of pseudopregnant Swiss Webster female 
mice. The presence of integrated plg-ENV-3'LTR in pups was de- 
termined by hybridization of a Southern blot of PstI-digested tail 
DNA to a 32p-labeled 870-bp BamHI-PstI fragment of the FMuLV 
env  gene probe (25). Mice containing  the plg-ENV-hGH  trans- 
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1.3-kb PstI fragment of hGH probe (26). Transgene-positive  lines 
were bred for at least three generations to document stable trans- 
mission of the transgene before further analysis. 
RNA Blot Analysis.  Total  cellular KNA from various tissues 
was isolated for analysis of gene expression by the guandinium- 
isothiocyanate/CsC1 method (31). The RNA samples were sub- 
jected to electrophoresis in 1% agarose-formaldehyde  gels, trans- 
ferred to nitrocellulose membranes (Schleicher & Schuell, Inc., 
Keene, NH), and hybridized to an 870-bp BamHI-PstI fragment 
of the FMuLV env gene (25) labeled with 32p by random priming 
(32). For selected studies, the KNA was obtained from enriched 
B cell populations purified from spleen cells by panning on dishes 
coated with rabbit anti-mouse Ig (33), or from enriched T cell 
populations purified from the nonadherent cells removed from the 
anti-Ig plates by passage through nylon wool columns (34). 
Purification of  FMuLg Envelope Proteins  Expressed in TG Lympho- 
cytes.  Af~nity-purified  goat antibody (IgG) against the gp70 enve- 
lope of pauscher murine leukemia virus (RMuLV) and crossreac- 
tire with FMuLV (NCI/BCB Repository, Bethesda, MD) was 
oxidized and coupled to an Aft-Gel Hz hydrazide  gel column (Bio- 
Pad Laboratories,  Richmond, CA) (35). Spleen  cells from plg-ENV 
TG mice or non-TG littermates were resuspended in lysis buffer 
containing 20 mM Hepes (pH 7.3), 1 mM EDTA, 50 mM NaC1, 
and 0.4% NP40, homogenized, and centrifuged at 500 g for 10 
min. The whole cell lysates were applied to the antibody affinity 
column and washed through with 0,5 M NaC1 in 0.1 M Tris buffer, 
pH 8.0. The absorbed FMuLV  envelope  proteins were subsequently 
eluted with 3 M potassium thiocyanate in PBS. 
Western Blot.  The protein  samples eluted from  the a~nity 
columns and unpurified splenocyte lysates were fractionated by 
reducing SDS-PAGE (10%) and electroblotted onto nitrocellulose. 
The blot was blocked 1 h at room temperature with 5% nonfat 
milk in TTBS (20 mM Tris, 500 mM NaC1, 0.05% Tween-20, pH 
7.5), and probed for 2 h with goat antiserum to gp70 diluted 1:300 
in TTBS. The blot was subsequently washed three times for 10 
min each in TTBS, and incubated for 1 h with an 12SI-labeled 
affinity-purified  rabbit anti-goat Ig (2  x  10  s cpm/ml) in TTBS. 
The washed filter was exposed to Kodak X-omat XAR-5 film at 
-70~  with intensifying screens. 
Immunization.  6-8-wk-old mice were inoculated via tail scratch 
with 107 PFU of recombinant vaccinia-FMuLV  env (vac-env) virus 
or vaccinia (vac) virus. After a delay  of at least 3 wk, spleen cells 
from primed mice were obtained for in vitro analysis.  For adoptive 
transfer experiments, donor mice were boosted with a second dose 
of virus 3 wk after the initial priming. 
In Vitro T Cell Proliferation Assay and IL2 Assay.  T cell prolifer- 
ative responses to FMuLV  envelope  were evaluated  as described (36). 
Briefly, in vivo primed spleen responder ceils were cultured with 
either irradiated stimulator cells or UV-inactivated  virus in 96-well 
flat-bottomed plates. The origin, preparation, and number of re- 
sponder ceils and stimulator cells, as well as total length of the 
culture  period, are  indicated in  each table or  figure  legend. 
[3H]TdR (20 mCi/mmol; New England Nuclear, Boston, MA), 
1.0/zCi/well,  was added for the final 24 h of culture. The Ib2 
activity present in cell-free culture superuatants was determined 
by measuring [3H]TdK  uptake by CTLL, an IL-2-dependent  T cell 
line (37). 
Adoptive Cell Transfer.  Immune splenocytes  were obtained from 
B6/Thy-l.1 mice immunized with vac-env or vac as described above. 
10  s spleen cells were injected intraperitoneally into plg-ENV TG 
mice and non-TG control mice. To promote in vivo proliferation 
of transferred  immune T cells, irradiated FBL tumor cells (107) and 
human rlL-2 (5,000 U/d for 6 d) were also injected  intraperitoneally 
into selected groups of recipient mice (38). Animals were killed 
2, 4, and 12 wk later, and the spleens, mesenteric lymph nodes, 
and thymuses were removed and processed for histologic exami- 
nation. 
Histology.  Tissues  were fixed  in 10% neutral buffered formalin, 
embedded in  paraffin, sectioned, and  stained with  hematox- 
ylin/eosin. Veterinarian  pathologists reviewed the slides to evaluate 
the lymphoid tissues for pathologic injury. 
Analysis of  Pe@heral Blood T and B Cells on the FACS  |  Single 
cell suspensions of RBC-lysed peripheral blood cells were labeled 
with either  FITC-conjugated monoclonal anti-Thy-l.2 (Becton 
Dickinson Monoclonal  Center, Sunnyvale,  CA) or FITC-conjugated 
goat anti-mouse Ig serum (Tago Inc., Burlington, CA) and ana- 
lyzed on the FACS  |  (39). 
Adoptive Chemoimmunotherapy (ACIT).  This model, as previ- 
ously described (17, 20), consists of treating mice bearing estab- 
lished disseminated  FBL leukemia  with a combination of nonlethal 
noncurative chemotherapy  and adoptively  transferred  immune cells. 
Briefly, on  day  0,  plg-ENV  TG  mice  were inoculated  in- 
traperitoneally with 5  x  10  ~ viable FBL leukemia cells. By day 
5, after tumor cells had disseminated, mice were treated with 180 
mg/kg cyclophosphamide  (CY) intraperitoneally, followed in 5 h 
by adoptively transferred donor cells. Donor splenocytes  obtained 
from B6 mice primed with vac-env or vac as described above were 
enriched for T  cells by passage through a nylon wool column. 
Previous studies have  demonstrated that therapy on day 5 with im- 
mune T cells alone has no apparent antitumor effect, in part due 
to the large tumor burden (17, 40), but that combined treatment 
with CY plus immune T cells can mediate complete tumor elimi- 
nation (17). The major contribution of CY in this model appears 
to be a reduction of the tumor burden to a size small enough to 
permit effective  expression of the antitumor activity of transferred 
immune T cells (17). 
Results 
Generation of TG Mice and Expression of the FMuLV env 
Transgene in Lymphoid  Tissues.  To generate TG mice ex- 
pressing the FMuLV env gene in the lymphoid lineage, two 
transgene construction strategies were used. The first approach 
was to ligate a 2.2-kb mouse E/z/P# segment to a 4.1-kb 
fragment of FMuLV containing the SD, SA, env gene, and 
3'LTK sequences (see Materials and Methods) to generate the 
plg-ENV-YLTR fusion gene (Fig. 1). This construct resulted 
in expression  of the FMuLV env gene after transfection in 
vitro into SP2/0, a mouse myeloma cell line (41). However, 
in seven TG founder animals derived from microinjection of 
the 6.3-kb EcolLI-HindlII fragment of plg-ENV-YLTK into 
B6 zygotes, no transgene expression was detected. Since the 
presence of introns can enhance gene expression in TG mice 
(42),  we adopted an alternative construction strategy. The 
2.2-kb FMuLV env gene (25) was inserted downstream of 
the 2.2-kb mouse E/z/P# regulatory segment and ligated to 
the 2.1-kb intron-containing hGH gene (Fig.  1, plg-ENV- 
hGH), such that the hGH sequences provide a polyadenyla- 
tion signal and intronic sequences to enhance transgene ex- 
pression, but do not produce hGH protein (42,  43).  After 
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Figure  1.  Map of the transgene constructs. The plg-ENV-hGH con- 
struct contains a 2.2-kb FMuLV ear gene (stippled bar) located downstream 
from a 2.2-kb combined #  enhancer (E/~, open bar)/Vh promoter (P#, 
arrow) fragment, derived from the mouse Ig heavy chain gene. This gene 
was fused into the first exon of a 2.1-kh genomic hGH gene (exons, filled 
boxes; introns, open boxes). The plg-ENV-3'LTK construct contains a 2.2- 
kb combined E/~/P/~ fragment fused to a 4.1-kb  segment including the 
splice donor site (SD), splice acceptor  site (SA),  env  gene (light  stippled 
bar), and 3' LTR sequence (dark stippled bar) of FMuLV clone 57. The posi- 
tion of the probe used to analyze gene expression,  an 0.87-kb fragment 
of the FMuLV env gene,  is located between the two solid arrows. 
microinjection of the 6.5-kb linearized  plg-ENV-hGH hy- 
brid DNA fragment into pronuclei of B6 mouse zygotes, 
30 pups were born, with two containing the integrated plg- 
ENV-hGH transgene. Both founders (lines 3164 and 3170) 
passed the transgene to their progeny, but only line 3164 mice 
transcribed the FMuLV env transgene mRNA and expressed 
protein in lymphoid tissues  (Fig.  2). 
Total RNA from various tissues and cells from line 3164 
was isolated and analyzed by blot hybridization using a 32p. 
labeled 870-bp BamHI-PstI fragment of the FMuLV env gene 
(25) as the probe (Fig.  2).  The transgene-encoded FMuLV 
env transcript was found in lymphoid cells (T and B popula- 
tions) and organs (spleen and thymus) of pIg-ENV TG mice, 
and was expressed at much lower levels  than in the FBL tumor. 
The transcript was not detected in brain, kidney, or liver. 
Efforts to identify the transgene-encoded FMuLV envelope 
protein in lymphoid cells by immunofluorescence, immuno- 
cytochemistry, and Western blotting techniques were unsuc- 
cessful, although these techniques all detected the protein in 
the FBL tumor. Since conventional antibody assays usually 
require a minimum of several thousand to one hundred thou- 
sand protein molecules for detection (44, 45), a more sensi- 
tive method for detecting protein was explored. Potential 
FMuLV protein present in a TG spleen cell lysate was purified 
by immunoaffinity  chromatography, a method that can achieve 
1,000-10,000-fold  protein purification (46). The protein at- 
tached to the column was eluted and tested for the presence 
of FMuLV envelope by Western blot analysis (Fig. 3). Using 
this strategy, the transgene-derived FMuLV envelope precursor 
protein  gp85  e~v  and  the  processed  glycosylated  protein 
gp70  env were detected from TG spleen ceUs. As a negative 
control, non-TG littermates derived from matings of line 3164 
were studied, and no mRNA or protein was detected (Figs. 
2 and 3). 
To determine if the low level of FMuLV  env  expression 
in TG lymphocytes is sufficient for recognition by T  cells, 
the ability of FMuLV envelope-specific T cells to proliferate 
in  response  to  irradiated  FMuLV  env +  TG  lymphocyte 
stimulator cells was assessed (Fig. 4). Irradiated spleen cells 
from non-TG B6 mice were unable to trigger proliferation 
of either the CD4 + T cell clone B10, a previously described 
gp70-specific clone of B6 origin (47),  or immune spleen T 
cells from B6 mice primed with a vaccinia-FMuLV env recom- 
binant  virus  (vac-env).  In contrast,  irradiated TG FMuLV 
env +  spleen lymphocytes, as well as two other FMuLV env + 
stimulators,  FBL cells and  UV-inactivated FMuLV virus, 
stimulated both types of FMuLV envelope-specific  T  cells. 
Thus, the amount of env  expressed in TG cells can, under 
appropriate conditions, be recognized by envelope-specific T 
cells and stimulate T  cell responses. 
Figure  2.  Specific  expression of FMuLV era, mP,  NA in lymphoid tissues 
from pIg-ENV TG mice. 2/~g of total R.NA from cultured FBL tumor 
cells and 20/~g of total cellular RNA from the indicated tissues and lym- 
phocytes of a plg-ENV TG mouse (line 3164) and a non-TG littermate 
were fractionated by electrophoresis  in a 1%  agarose-formaldehyde  gel, 
transferred  to  nitrocellulose,  and hybridized with  a 32P-labeled 870-bp 
BamHI-PstI fragment of the FMuLV env gene. The migration of eukary- 
otic ribosomal RNAs, as markers,  is indicated. 
Figure  3.  Expression of FMuLV envelope proteins in lymphocytes of 
TG mice. Spleens were obtained from 6-wk-old pIg-ENV TG mice and 
non-TG littermates. The whole spleen cell lysates were prepared and purified 
for FMuLV envelope proteins by immunoa~nity chromatography. The 
protein samples were separated by reducing SDS-PAGE (10%),  electro- 
blotted onto nitrocellulose, and probed using affinity-purified  goat antiserum 
to gpTO  envelope and a 12SI-labeled  second-step rabbit anti-goat antibody 
(see Materials and Methods). Lane 1,100 #g FBL cell lysate; lane 2, 100 
/~g spleen cell lysate from non-TG littermates; lane 3, 10/~g a~nity-purified 
proteins from spleen cell lysate of non-TG littermates; lane 4, 10/r  af~nity- 
purified proteins from spleen cell lysate of TG mice; lane 5, 100/~g spleen 
cell lysate from TG mice. Mobilities of prestained molecular mass stan- 
dards are indicated at the right. 
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Figure 4.  Ability  of  FMuLV envelope- 
expressing  TG  lymphocytes  to  stimulate 
proliferative  responses  in FMuLV  envdopc-reac- 
tire T cells. Spleen cells were obtained from 
B6 mice primed with vac.env and enriched for 
T cells by passage over nylon wool columns. 
10  s vac-env-primed  splenic T cells or 5  x  104 
B10 cells, an envelope-specific  CD4 + T cell 
clone, were cultured for 3 d with 5 x  10  s ir- 
radiated B6 splenocytes  (1,700  rad) as APC plus 
indicated stimulators, including 2  x  10  s ir- 
radiated TG or non-TG  spleen cells (1,700  tad), 
2 x  104 irradiated FBL cells (10,000 tad), and 
5  /~g/ml of UV-inactivated FMuLV virion 
(FMuLV). [3H]TdR (1.0/~Ci/well) was added 
during the final 24 h of  culture. Data presented 
were calculated as described in Table 1. 
T  Cell Tolerance to FMuLV Envelope Antigen in plg-ENV 
TG Mice.  To evaluate T cell responsiveness in plg-ENV TG 
mice to FMuLV envelope antigen,  groups of TG mice and 
Table  1.  FMuLV Envelope-specific T  Cell Proliferation and 
IL-2 Production 
Mixed leukocyte 
tumor culture*  IL-2 
T  cell  production 
Responder  Stimulator  proliferation  (CTLL) 
AclJm*  AcpmS 
TG cxvac-env  (FBL)x  439  152 
FMuLV  534  398 
Vac  29,461  20,952 
B6 ccvac-env  (FBL)x  19,493  8,906 
FMuLV  21,002  14,748 
Vac  32,145  31,140 
B6  (FBL)x  591  72 
FMuLV  664  62 
Vac  720  226 
* ILesponder spleen cells were obtained from plg-ENV TG mice or non- 
TG B6 littermates previously immunized with vac-env or left unprimed. 
To assay the T cell proliferative  response, responder cells (5  x  10S/well) 
were cultured for 3 d with 104 irradiated (FBL)x or (B6)x spleen cells, 
5/~g/ml UV-inactivated  FMuLV virions (FMuLV), or vaccinia virus (vat) 
at a 1:1 multiplicity of infection. 1.0/~Ci/well  [3H]TdR was added for 
the final 24 h of culture. To assay IL-2 production, responder CD4 + 
T cells were enriched from spleen cells by negative selection (19), and 
2  x  104 CD4 + responder T  cells were cultured with  the indicated 
stimulators at the same responder/stimulator  ratio used in the T cell 
proliferation assay. After 40 h of incubation, cell-free supernatants were 
collected and assayed for IL-2 activity by measuring CTLL proliferation 
(37). 
t Acpm, are the mean cpm of triplicate cultures with antigen stimula- 
tion minus the mean cpm of triplicate  cultures without antigen stimulation. 
$ Data represents the IL-2 activity present in a 1:4 dilution of the cul- 
ture supernatant. Acpm were calculated as the proliferative response of 
CTLL cells, an IL-2 indicator line, induced by supernatants from antigen- 
stimulated cultures minus the response with supernatants from unstimu- 
lated cultures. A representative experiment is presented. 
non-TG littermates were inoculated via tail scratch with vac- 
env. Spleen cells were obtained a minimum of 3 wk after im- 
munization, and the response to FMuLV envelope was deter- 
mined by in vitro T  cell proliferation and IL-2 production 
assays (Table 1). As expected, T cells from vac-env-primed non- 
TG mice responded to stimulation with FBL tumor cells or 
UV-inactivated  FMuLV  virus  both  by  proliferating  and 
producing IL-2. In contrast, T cells from vac-env-primed TG 
mice exhibited no response to either preparation of FMuLV 
envelope antigen. TG T  cells primed with vac-env responded 
normally to vaccinia virus, affirming that such T  cells were 
infected with vaccinia virus and were competent to respond. 
Responsiveness to envelope was also assessed by examining 
resistance of TG and non-TG mice to challenge with FBL 
tumor.  Unimmunized TG mice and non-TG littermates all 
died within  20  d  of challenge  with  5  x  105 viable  FBL 
tumor cells (Table 2). Prior immunization with vac-env pro- 
tected 14 of 16 non-TG mice from challenge with this tumor, 
as demonstrated by rejection of the viable tumor cells and 
long-term survival. In contrast, vac.env-immunized TG mice 
remained susceptible to FBL tumor challenge, with all mice 
dying of progressive tumor growth by day 20. Moreover, vac- 
env immunization did not delay tumor progression and time 
of death in TG mice.  The results  of these in vitro and in 
vivo assays  suggest that T  cells in TG mice are tolerant to 
the FMuLV envelope antigen. 
Adoptive  Transfer of FMuLV Envelope-immune T  Cells into 
pIg-ENV TG Mice Does Not Cause Detectable Autoimmune In- 
jury in FMuLV env-expressing Lymphoid Tissues.  TG mice ex- 
pressing FMuLV env provide a model for evaluating the con- 
sequences of adoptive therapy with  tumor-reactive T  cells 
that can potentially recognize normal tissues. Thus, FMuLV 
envelope-immune  spleen  cells  obtained  from  congeneic 
B6/Thy-l.1 donor mice primed with vac-env were injected 
into pIg-ENV TG mice. To promote the proliferation of trans- 
ferred FMuLV envelope-specific donor T  ceUs in recipients, 
irradiated FBL tumor cells and/or rIL-2 were also injected 
into selected groups of recipient mice (Table 3). Mice were 
killed at multiple time points after cell transfer, and evalu- 
ated for immune-mediated injury. No detectable histopatho- 
logic changes were observed in the TG lymphoid organs, and 
no decrease in the number of peripheral blood T  or B lym- 
1685  Hu et al. Table  2.  Failure  to Induce Protective Immunity against  FBL  Tumor Challenge  in plg-ENV  TG Mice after Immunization  with vac-env 
Percent survival*  Tumor 
Mice  No./group  Immunization*  challenges  15 d  20 d  60 d 
TG  16  vac-env  FBL  38  0  0 
15  vac  FBL  40  0  0 
15  None  FBL  46  0  0 
B6  16  vac-env  FBL  100  88  88 
16  vac  FBL  43  0  0 
16  None  FBL  38  0  0 
* The cumuhtive data of two independent experiments  are provided,  with percent  survival recorded at  15, 20,  and 60 d after tumor challenge. 
* plg-ENV TG mice and non-TG B6 littermates  were immunized via tail scratch with vac-env or vac, or left unprimed as described in Materials 
and Methods. 
S Mice were challenged intraperitoneally  with 5  x  10  s viable FBL leukemia cells 4 wk after the immunization. 
phocytes was detected. The TG recipients of transferred im- 
mune T  cells appeared healthy, gained weight normally, and 
did not exhibit runting, the most common clinical features 
of GVHD  (48).  These data suggest  that  the low levels of 
FMuLV envelope expressed in TG lymphoid tissues may not 
be capable of stimulating envelope-reactive T  cells in vivo 
despite the fact that the TG cells can stimulate such T  cells 
under appropriate  in vitro conditions. 
Table  3.  Effect of Adoptive  Transfer  of FMuLV Envelope-immune T  Cells  into pIg-ENV  TG Mice  on the  TG Lymphoid Compartment 
Blood lymphocyte counts* 
Additional 
treatment*  Histology of  T  cells  B  Cells 
lymphoid 
Donor cells  s  Recipients  FBLx  rlL-2  tissues  PI  Day 0  Dat  28  Day 0  Day 28 
vac-env-primed  B6/Thy-l.1 
spleen T  cells 
vac-primed  B6/Thy-l.1 
spleen T  cells 
TG 
B6 
x  103/mm 3 
-  -  Normal  5.05  •  0.31  5.21  •  0.25  1.91  _  0.12  2.13  •  0.16 
+  -  Normal  4.95  _+  0,34  7.31  _+  0.51  1.85  _+  0.14  3.01  •  0.25 
-  +  Normal  5.10  •  0.41  5.51  •  0.45  1.92  •  0.13  2.21  •  0.24 
+  +  Normal  4.91  •  0.25  8.23  _+  0.75  2.01  •  0.17  3.51  •  0.31 
-  -  Normal  4.85  •  0.37  5.02  •  0.35  1.93  •  0.14  1.90  •  0.11 
+  -  Normal  5.07  •  0.29  8.11  •  0.85  2.07  •  0.17  3.62  •  0.37 
-  +  Normal  4.98  •  0.41  5.24  •  0.36  1.87  •  0.15  2.07  •  0.16 
+  +  Normal  5.15  _+  0.32  9.76  •  0.98  1.98  •  0.18  4.05  _+  0.38 
TG  -  -  Normal  4.82  •  0.40  4.97  _+  0.31  2.10  •  0.12  2.15  •  0.17 
B6  -  -  Normal  5.21  •  0.39  5.18  •  0.43  1.79  •  0.19  2.01  •  0.14 
* The indicated recipients were injected intraperitoneally  with 107 irradiated  (12,000 tad)  FBL cells and/or 5,000  U/d for 6 d of human rlL-2. 
Venous blood samples were obtained from recipient mice before (day 0) and after (day 28) adoptive transfer of B6/Thy-l.1 donor T cells. Total 
white blood cells were counted in a hemocytometer,  the RBC were lysed, and the percent host peripheral blood T and B cells subsequently enumerated 
on a FACS  |  with the use of fluoresceinated monoclonal anti-Thy-l.2 or goat anti-mouse Ig serum. 
S Donor spleen cells were obtained from B6/Thy-l.1 mice immunized with either  vac-env or vac as described in Materials and Methods.  Unfrac- 
tionated spleen cells (10  s) were injected intraperitoneally  into indicated plg-ENV TG mice or non-TG B6 littermates.  The data from two experi- 
ments containing a total of four mice/group are presented. 
II Animals were killed 2, 4, and 12 wk after transfer of donor cells, and the spleens, mesenteric lymph nodes, and thymuses were removed for histo- 
logic examination. Normal histology  means that no pathologic  changes in cell number, distribution, or architecture  were  observed. 
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Figure  5.  Efficacy of transferred T cells immune to FMuLV envelope 
in the therapy of disseminated FBL leukemia in pIg-ENV TG hosts. Im- 
mune spleen cells were obtained  from B6 mice immunized with vac-env 
or vac and were enriched for T cells by passage over nylon wool columns. 
pIg-ENV TG ice (six mice/group) were inoculated intraperitoneally  with 
5  x  106 viable FBL tumor cells on day 0 and were left untreated (NO 
THERAPY),  treated on day 5 with 180 mg/kg CY (CY ALONE), CY 
plus 5  x  107 vac-primed B6 T cells, or CY plus 5  x  107 vac.env-primed 
B6 T  cells. 
Expression of FMuLV env in TC, Lymphoid Tissue Does Not 
Interfere with Activity of Transferred FMuLV Envelope-immune 
T  Cells  in  pIg-ENV  TG  Recipients.  Previous  studies  in 
H-2K  b TG mice showed that expression of the H-2K  b trans- 
gene in peripheral tissue could tolerize adoptively transferred 
H-2Kb-reactive T cells (49),  suggesting that even fully ma- 
ture peripheral T cells can be the targets for tolerance induc- 
tion. Such tolerance induction would explain the failure to 
observe autoimmune tissue injury in the adoptive transfer 
studies described above. This issue was further evaluated in 
an adoptive therapy model for the treatment of disseminated 
leukemia with a combination of chemotherapy and immune 
T cells (17). In this model, complete eradication of the tumor 
is dependent on the long-term persistence and function of 
transferred tumor-specific T cells (39) and, consequently, in 
vivo tolerance induction would be expected to interfere with 
the therapeutic antitumor activity of T cells. TG mice were 
inoculated with 5  x  106 viable FBL on day 0 and, if given 
Table  4.  FMuLV Envelope-specific Proliferative Response of Donor 
no therapy, had a median survival of 12 d (Fig. 5). Treatment 
with CY alone on day 5 prolonged the median survival to 
day 25, but all mice still died of progressive tumor growth. 
As an adjunct to CY,  adoptive transfer of 5  x  107 splenic 
T cells from vat-primed B6 mice had no significant effect on 
survival.  In contrast, therapy with CY plus 5  x  107 vac-env- 
primed splenic T cells prolonged survival and cured >80% 
of mice. Moreover, histologic analysis  of these cured mice 
revealed no evidence of autoimmune injury in the lymphoid 
tissue.  Thus, transferred FMuLV envelope-immune T  cells 
can maintain antitumor activity and mediate eradication of 
FMuLV env + FBL cells in TG hosts, despite persistent ex- 
posure to FMuLV envelope expressed in lymphoid tissues. 
The ability of transferred immune T cells to retain activity 
in TG recipients was examined in an additional model. Im- 
mune spleen cells from B6 mice primed with vac-env were 
transferred into TG animals. The recipients were then boosted 
with vac-env and, 4 wk later, spleen cells were obtained and 
assessed for T  cell reactivity to FMuLV envelope (Table 4). 
Spleen cells recovered from TG recipients of vac-env-primed 
donor T  cells demonstrated proliferative responses to FBL, 
FMuLV virus, and vaccinia. In contrast, spleen cells from TG 
mice that did not receive transferred env-reactive donor T cells 
responded to vaccinia, but did not respond to FBL or FMuLV. 
The  cumulative  results  demonstrate  that  FMuLV  enve- 
lope-specific immune donor T cells are not inactivated when 
transferred into pIg-ENV TG mice, retain responsiveness to 
an env-expressing tumor, and do not induce readily demon- 
strable autoimmune injury in lymphoid tissues expressing low 
levels of the transgene product. 
Discussion 
In the present study we have described a TG mouse model 
useful for addressing some of the issues related to the use 
of tumor-associated antigens not uniquely expressed on trans- 
formed cells as targets for adoptive T cell therapy of human 
tumors. The model uses a retrovirally transformed leukemia 
FBL that expresses immunogenic retrovirus-encoded antigens, 
and TG mice that express one of these proteins, FMuLV enve- 
lope, under the control of a lymphoid-specific promoter. Our 
results demonstrate that expression of the FBL tumor an- 
T  Cells Recovered  from pIg-ENV TG Recipients 
In vivo pretreatment*  T cell proliferative response* 
Responder  Adoptive transfer  Immunization  FBL  FMuLV  Vac 
Acpm 
TG  vav-env-primed B6  spleen cells  vac-env  6,062  5,203  52,206 
TG  Medium  vac.env  524  -  423  51,841 
* PIg-ENV TG mice injected intraperitoneally  with medium or 10  s spleen cells from B6 mice previously primed with vac-env, and then immunized 
via tail scratch  with vac.env. 
t 4 wk after in vivo pretreatment, spleen cells were obtained  and assessed for T cell proliferative  responses, as described in Table 1. A representative 
experiment is presented. 
1687  Hu et al. tigen in normal cells of the same lymphohematopoietic lin- 
eage as the tumor, but at substantially lower levels than the 
tumor, can induce T  cell tolerance, as reflected by the in- 
ability to elicit an envelope-specific  T cell response after im- 
munization of TG mice with a recombinant vaccinia virus 
expressing the envelope antigen. However, the expression of 
low levels of the envelope in TG mice does not interfere with 
the therapeutic efficacy of adoptively transferred envelope- 
specific T  cells, and such cells can mediate tumor rejection 
without inducing autoimmune injury in TG mice. 
The TG mice were constructed by introducing the FMuLV 
env gene into B6 mice under the control of the Ig E/~/P/~ 
promoter. This resulted in selective expression of env in T 
cells as well as B cells, as predicted from other TG mouse 
strains containing genes controlled by the Ig promoter (50). 
Although our results demonstrate that the TG mice are tolerant 
to the transgene-encoded FMuLV envelope, the basis for such 
tolerance in these mice has not been fully clarified.  Analysis 
in normal B6 mice ofTCR V~/gene usage by T cells respon- 
sive to FMuLV envelope has failed to detect a dominant V~ 
gene (data not shown), and thus it is not possible to deter- 
mine if a distinct envelope-reactive T cell population has been 
clonally deleted. The expression of envelope in T and B cells 
assures that this antigen is present in the thymus during thymic 
ontogeny, but does not a priori indicate that clonal deletion 
will occur, since neither cell type has been definitively shown 
to mediate negative selection in the thymus. 
Alternative nondeletional peripheral mechanisms of toler- 
ance include induction of peripheral anergy, such as by im- 
proper triggering and/or downregulation of the TCR,  or 
active suppression (6-8, 51). This latter mechanism of sup- 
pression  seems  improbable,  since  adoptively  transferred 
envelope-reactive T cells were effective in tumor therapy in 
TG  mice.  Moreover,  the  demonstration  that  transferred 
envelope-reactive T cells can be recovered from TG mice with 
retention of function suggests that, if peripheral anergy to 
envelope is being induced in TG mice, the peripheral mecha- 
nism is only operative to prevent priming of naive T  cells 
and is not operative with T cells previously primed and/or 
activated in vitro. This is entirely consistent with the known 
more rigid requirements for inducing a primary rather than 
activating a secondary T cell response (52). Definitive deter- 
mination of the mechanism responsible for tolerance induc- 
tion and maintenance will likely require the construction of 
TG mice expressing an envelope-specific  TCR gene, such as 
could be derived from the B10 T cell clone. Such TCR-TG 
mice could then be mated to the env-TG  mice, and the fate 
ofT cells through the thymus and periphery could be assessed. 
Adoptive transfer of FMuLV envelope-immune T cells into 
plg-ENV TG mice did not result in any apparent autoim- 
mune disease,  as reflected by the absences  of pathological 
changes in TG lymphoid tissues,  decline in the number of 
host-circulating T and B cells despite the expression of enve- 
lope by these cells, or clinical features of GVHD. This does 
not reflect clonal inactivation of the transferred T cells, since 
such cells mediated in vivo tumor reactivity and could be 
recovered with retention of activity after transfer into TG 
mice. Previous studies from our laboratory have demonstrated 
that FMuLV envelope selectively induces in B6 mice only an 
MHC class II-restricted CD4 § T cell response, and conse- 
quently no MHC class I-restricted CD8 + cytolytic T  cell 
response to envelope is detectable after immunization with 
either an envelope-expressing tumor or a recombinant vac- 
env (19).  Thus,  the lack of autoimmune tissue destruction 
could reflect a requirement for both CD4 §  and CD8 + T 
cells for autoimmune injury, as has been observed in autoim- 
mune diabetes in NOD mice (53) and in some TG models 
of diabetes due to ~  cell injury (12,  13). However, this hy- 
pothesis is not strongly supported by several pieces  of ex- 
perimental evidence. First, envelope-specific  CD4 + T  cells 
can mediate in non-TG B6 mice complete elimination of dis- 
seminated FBL tumor, in the absence of any contribution 
by  CD8 +  T  cells  (18-20),  affirming  the  ability  of this 
effector population  to promote tissue destruction in vivo. 
Second, in models of GVHD with strains of mice differing 
only at class II,  CD4 + T  cells can mediate lethal GVHD 
(54,  55).  Finally,  in mice expressing a class II transgene in 
pancreatic acinar cells, T  cells restricted to this novel class 
II antigen can mediate pancreatic tissue destruction (56). Thus, 
CD4 + T cells have demonstrable activity as effector cells in 
many in vivo models, presumably in part through the secre- 
tion of cytokines and activation of other cytolytic cells such 
as macrophages and NK cells. 
Another possible explanation for the apparent lack of in- 
jury to normal tissues is that the expression of FMuLV enve- 
lope in TG lymphoid tissues  is below the level required to 
serve as an effective target for CD4 + T cell-mediated tissue 
damage. The FMuLV envelope protein was detected in these 
studies in TG lymphoid tissues at a lower level than that found 
in FBL tumor cells. However, TG env +  lymphocytes were 
capable of stimulating in vitro proliferation by envelope-reactive 
immune T cells and the envelope-specific B10 clone (Fig. 4). 
Thus,  the same TG lymphocytes that induce tolerance to 
priming in TG mice can stimulate primed envelope-reactive 
T cells in vitro, but appear to be neither stimulatory nor sus- 
ceptible to injury by primed envelope-reactive T cells in vivo. 
Potentially, the in vitro stimulatory conditions reflect condi- 
tions disparate from those encountered in vivo with TG lym- 
phocytes, and current studies are exploring if this reflects con- 
centration of antigen and/or the stimulatory or processing 
activity of a distinct accessory cell or APC. 
The results provide encouragement for pursuing TAA de- 
tected in limited amounts in normal tissues as potential targets 
for T cell tumor therapy. Studies in TG mouse lines expressing 
other proteins have demonstrated that it may be possible to 
induce in vitro T cell responses to antigens encoded by trans- 
genes despite apparent nonreactivity in vivo. The use of selected 
APC in vitro, such as dendritic cells that can stimulate pri- 
mary in vitro T cell responses (57), may improve the ability 
to generate such responses.  Alternatively, immunization in 
vivo with infectious viruses containing the protein of interest 
(12, 13), or with concurrent administration of exogenous IL-2 
to overcome an initially deficient helper T cell response (58), 
has been shown to induce T  cell responses to presumably 
1688  Expression  of Tumor Antigens in Transgenic  Mice tolerogenic TG proteins. In our studies, a recombinant vac- 
cinia virus failed to elicit responses to the transgenic TAA, 
but other viruses need to be explored. Further studies in this 
and related lines of TG mice, in which the expression of TAA 
is controlled by promoters resulting in selective expression 
in nonlymphoid tissues,  may help identify principles for the 
development of methods to generate tumor-reactive T  cells 
with potential therapeutic activity. 
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